FAST NEWS: JW Therapeutics Announces Two Major Senior Appointments

The latest: Immunotherapy products maker JW (Cayman) Therapeutics Co. Ltd. (2126.HK) announced two major new appointments, including Dr. Shaun Paul Cordoba as its chief scientific officer and Raymond J. Hage Jr. as its senior vice president for corporate development. Looking Up: Drug startups like JW Therapeutics often have no revenue, and thus investors will often look at their executive rosters to try to determine the company’s chances for success. The company said Cordoba is currently the world’s third biggest patent holder for chimeric antigen receptor (CAR) technology that is one…

Read More »

Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale

The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: •      Less than two weeks after JW Therapeutics received regulatory approval to commercialize its core product in China, key early investor Temasek sold all of its stake •      JW Therapeutics’ stock now trades nearly 30% below its IPO price, as numerous obstacles remain in the march to commercialize its cutting-edge cancer treatment By Warren Yang It seems a major breakthrough for JW (Cayman)…

Read More »